Log In
Print this Print this

OBP-801, YM753

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionHistone deacetylase (HDAC) inhibitor
Molecular Target Histone deacetylase (HDAC)
Mechanism of ActionHistone deacetylase (HDAC) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationRenal cancer
Indication DetailsTreat kidney cancer
Regulatory Designation
PartnerOncolys BioPharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today